A secondary analysis of exploratory outcomes from a randomized phase 2 clinical trial (NCT05687903) reported moderate- to large-magnitude effects of oveporexton (TAK-861; Takeda Pharmaceuticals), an oral orexin receptor 2, on cognitive measures in…
Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 | NeurologyLive
